Valbenazine (US Brand name Ingrezza®) is a vesicular monoamine transporter 2 (VMAT2) inhibitor. Here is basic information about this medication. Other articles on this website with more advanced information and tips related to this medication are linked to under Related Pages below.
Treatment of adults with tardive dyskinesia
The initial dose is 40 mg once daily orally. After one week, increase the dose to the recommended dose of 80 mg once daily.
Administration and instructions
Valbenazine may be administered with or without food.
In patients with moderate and severe hepatic impairment, the recommended dose is 40 mg daily.
Based on tolerability, consider dose reduction for known poor CYP2D6 metabolizers.
Dosage forms and strengths
Capsules: 40 mg and 80 mg
Potential side effects
Please see THIS PAGE for a handout listing both the common and less common side effects of this medication along with the percentages of patients who report them.
Important! Please refer to the full Prescribing Information (see link below) before prescribing this medication.
Copyright 2017, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons, or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.